Karl L.M. Rothweiler

Aglaia Management BV is an independent venture capital investment firm headquartered in Bilthoven, the Netherlands. In 2003, Aglaia was co-founded by Mark Krul and Karl Rothweiler.

Modra Pharmaceuticals BV designs and develops oral formulations of commonly used anti-cancer drugs. It is a clinical-stage company which develops series of oral formulations of existing IV anticancer drugs which reduce the side effects common to IV formulations, thereby improving patient convenience. The company was founded in June 2010 and is headquartered in Amsterdam, the Netherlands.

ORCA Therapeutics BV designs and develops virotherapy drugs. The firm is a biopharmaceutical company focusing on the development of new anti-cancer treatments using Oncolytic Replication Competent Agents. It has a platform of technologies which are predominantly based on engineered oncolytic adenoviruses. The company was founded in 2005 and is headquartered in Nijmegen, the Netherlands.

ISA Pharmaceuticals BV operates as a clinical-stage immunotherapy company. The firm develops novel therapeutic vaccines for cancer and infectious diseases. Its product portfolio builds on its proprietary SLP-technology (Synthetic Long Peptide) for the development of therapeutic vaccines. The firm holds the exclusive rights to LUMC's patent families for amongst others, the development of therapeutic vaccines. The company was founded by Cornelis J. M. Melief in 2004 and is headquartered in Leiden, the Netherlands.

InteRNA Technologies BV develops RNA technologies and applications. It provides drug discovery and development services for the treatment of cancer based on the proprietary microRNA (miRNA) functions. The company develops miRNA-based therapeutics that control genes connected in signal transduction pathways and biological processes as a part of cancer initiation, progression and metastasis. InteRNA Technologies was founded by Edwin Cuppen and Eugene Berezikov in December 2006 and is headquartered in Nijmegen, the Netherlands.